Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism

BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when administered as a short‐acting preparation. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gostelow, R., Scudder, C., Keyte, S., Forcada, Y., Fowkes, R.C., Schmid, H.A., Church, D.B., Niessen, S.J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354018/
https://www.ncbi.nlm.nih.gov/pubmed/28145031
http://dx.doi.org/10.1111/jvim.14662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354018/
https://www.ncbi.nlm.nih.gov/pubmed/28145031
http://dx.doi.org/10.1111/jvim.14662

Ejemplares similares